At the time of writing, Vertex Pharmaceuticals, Inc [VRTX] stock is trading at $454.96, down -0.16%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VRTX shares have gain 4.11% over the last week, with a monthly amount glided 4.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] stock has seen the most recent analyst activity on December 03, 2025, when Morgan Stanley upgraded its rating to an Overweight but kept the price target unchanged to $516 for it. Previously, Scotiabank started tracking the stock with Sector Outperform rating on November 13, 2025, and set its price target to $495. On September 25, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $456 on the stock. Raymond James started tracking the stock assigning a Mkt Perform rating. Wells Fargo upgraded its rating to an Overweight but $460 remained the price target by the analyst firm on August 06, 2025. Wolfe Research downgraded its rating to Peer Perform for this stock on May 07, 2025. In a note dated May 06, 2025, Leerink Partners downgraded a Market Perform rating on this stock but restated the target price of $503.
For the past year, the stock price of Vertex Pharmaceuticals, Inc fluctuated between $362.50 and $519.68. Currently, Wall Street analysts expect the stock to reach $483 within the next 12 months. Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] shares were valued at $454.96 at the most recent close of the market. An investor can expect a potential return of 6.16% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
According to Vertex Pharmaceuticals, Inc [NASDAQ:VRTX], the company’s sales were 11.73B for trailing twelve months, which represents an 12.27% jump. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at 0.34%, Pretax Profit Margin comes in at 0.38%, and Net Profit Margin reading is 0.31%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.2 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 452.18 points at the first support level, and at 449.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 458.40, and for the 2nd resistance point, it is at 461.83.
Ratios To Look Out For
It is important to note that Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] has a current ratio of 2.36. As well, the Quick Ratio is 2.00, while the Cash Ratio is 1.1. Considering the valuation of this stock, the price to sales ratio is 9.84, the price to book ratio is 6.67 and price to earnings (TTM) ratio is 32.06.
Transactions by insiders
Recent insider trading involved WAGNER CHARLES F JR, EVP, CO & FO, that happened on Dec 03 ’25 when 14000.0 shares were sold. EVP, Chief Reg. & Quality Off., Tatsis Ourania completed a deal on Dec 03 ’25 to sell 4500.0 shares. Meanwhile, Executive Chairman LEIDEN JEFFREY M sold 63781.0 shares on Dec 03 ’25.
